Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology eraKazuyuki Numakura, Tomonori Habuchi, Takahiro Kojima et al.|Cancer Medicine|2021Cited by 22
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective studyShingo Hatakeyama, Chikara Οhyama, Sei Naito et al.|International Journal of Urology|2020Cited by 14
Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy eraSei Naito, Norihiko Tsuchiya, Tomoyuki Kato et al.|International Journal of Clinical Oncology|2021Cited by 10
Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective studyRenpei Kato, Wataru Obara, Sei Naito et al.|International Journal of Clinical Oncology|2022Cited by 10
External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective studyKazutaka Okita, Chikara Οhyama, Shingo Hatakeyama et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 8